# Necrotising enterocolitis biomarkers: a systematic review

**Authors:** Muhammad Ashhad Faizan, Iffat Khalid, Asten Yeo, Magdalina Mazheda Fadel, Alannah Mcmahon, Philip Gavigan, Saffron O’Neill, Eman Isweisi, Gregana Semova, Edna F. Roche, Aoife Branagan, Judith Meehan, Eleanor J. Molloy

PMC · DOI: 10.3389/fped.2025.1652566 · Frontiers in Pediatrics · 2026-01-12

## TL;DR

This systematic review identifies potential biomarkers for early detection of necrotising enterocolitis in preterm neonates.

## Contribution

The study compiles and evaluates biomarkers with high diagnostic accuracy for early-stage necrotising enterocolitis.

## Key findings

- Faecal and serum calprotectin showed high sensitivity and specificity for Bell's stage ≥II NEC.
- A panel of urine proteins (CST3, PEDF, RET4) and maternal human milk oligosaccharides demonstrated strong diagnostic accuracy.
- Interleukin 33 (IL-33) also exhibited high accuracy for early NEC detection.

## Abstract

Necrotising enterocolitis (NEC) is a severe acute inflammatory condition of the gastrointestinal tract that predominantly affects preterm neonates. The variable and often nonspecific clinical signs, followed by rapid progression into fulminant disease, and the lack of standardised definitions and biomarkers, make this condition notoriously difficult to diagnose. This systematic review aims to outline the inflammatory pathways involved in the pathogenesis of NEC and to identify potential biomarkers associated with the initial stages of disease progression.

Following the PRISMA guidelines, we conducted an electronic search of the available literature using the PubMed, Embase, and Cochrane electronic databases with the following search terms (“necrotizing enterocolitis” OR “necrotising enterocolitis” OR “NEC”) AND (“biomarker*” OR “biological marker”). Studies reporting data on the diagnostic accuracy of biomarkers for NEC were included. Results were restricted to full-text articles in English, available up to November 2024. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.

A total of 211 studies were screened, yielding 79 studies for analysis. Most studies evaluated the ability of biomarkers to differentiate Bell's stage ≥II NEC from controls or Bell's stage II from stage III. For identifying Bell's stage ≥II, faecal calprotectin (97.14% sensitivity, 100% specificity) and serum calprotectin (100% sensitivity, 96.4% specificity), as well as a panel consisting of urine proteins including Cystatin C (CST3), Pigment Epithelium Derived Factor (PEDF), and Retinol Binding Protein 4 (RET4) (96% sensitivity, 90% specificity), and maternal human milk oligosaccharide disialyllacto-N-tetraose DSNLT (90% sensitivity and specificity) demonstrated high sensitivity and specificity when sampled prior to or around the initial diagnosis of NEC. Interleukin 33 (IL-33) exhibited high accuracy.

PROSPERO CRD42024307046.

## Linked entities

- **Proteins:** CYSTATIN-C (cystatin-C)

## Full-text entities

- **Genes:** CST3 (cystatin C) [NCBI Gene 1471] {aka ADLDWA, ARMD11, HEL-S-2}, SERPINF1 (serpin family F member 1) [NCBI Gene 5176] {aka EPC-1, OI12, OI6, PEDF, PIG35}, RBP4 (retinol binding protein 4) [NCBI Gene 5950] {aka MCOPCB10, RDCCAS}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}
- **Diseases:** inflammatory (MESH:D007249), Bell's (MESH:D020330), III (MESH:C537189), NEC (MESH:D004760), necrotizing enterocolitis (MESH:D020345)
- **Chemicals:** disialyllacto-N-tetraose (MESH:C576246), DSNLT (-), oligosaccharide (MESH:D009844)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12833235/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12833235/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12833235/full.md

---
Source: https://tomesphere.com/paper/PMC12833235